ITT3235
ITT3235
- Catalog: ITT3235
- Gene/Protein: SLC22A5
- Product Description: Immunotag™ OCTN2 Polyclonal Antibody
385.0000
Price in reward points: 385
Your shopping cart is empty!
Antibody Specification | |
Datasheet | |
Target Protein | OCTN2 |
Clonality | Polyclonal |
Storage/Stability | -20°C/1 year |
Application | WB,ELISA |
Recommended Dilution | Western Blot: 1/500 - 1/2000. ELISA: 1/20000. Not yet tested in other applications. |
Concentration | 1 mg/ml |
Reactive Species | Human |
Host Species | Rabbit |
Immunogen | The antiserum was produced against synthesized peptide derived from human SLC22A5. AA range:300-349 |
Specificity | OCTN2 Polyclonal Antibody detects endogenous levels of OCTN2 protein. |
Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen |
Form | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
Gene Name | SLC22A5 |
Accession No. | O76082 Q9Z0E8 |
Alternate Names | SLC22A5; OCTN2; Solute carrier family 22 member 5; High-affinity sodium-dependent carnitine cotransporter; Organic cation/carnitine transporter 2 |
Description | solute carrier family 22 member 5(SLC22A5) Homo sapiens Polyspecific organic cation transporters in the liver, kidney, intestine, and other organs are critical for elimination of many endogenous small organic cations as well as a wide array of drugs and environmental toxins. The encoded protein is a plasma integral membrane protein which functions both as an organic cation transporter and as a sodium-dependent high affinity carnitine transporter. The encoded protein is involved in the active cellular uptake of carnitine. Mutations in this gene are the cause of systemic primary carnitine deficiency (CDSP), an autosomal recessive disorder manifested early in life by hypoketotic hypoglycemia and acute metabolic decompensation, and later in life by skeletal myopathy or cardiomyopathy. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Apr 2015], |
Protein Expression | Brain,Kidney,Lung,Trachea, |
Subcellular Localization | plasma membrane,integral component of plasma membrane,integral component of membrane,apical plasma membrane,brush border membrane,extracellular exosome, |
Protein Function | disease:Defects in SLC22A5 are the cause of systemic primary carnitine deficiency (CDSP) [MIM:212140]. CDSP is an autosomal recessive disorder of fatty acid oxidation caused by defective carnitine transport. Present early in life with hypoketotic hypoglycemia and acute metabolic decompensation, or later in life with skeletal myopathy or cardiomyopathy.,disease:Defects in SLC22A5 may be a cause of susceptibility to Crohn disease (CD) [MIM:266600]. CD is a form of remitting inflammatory bowel disease (IBD). CD may involve any part of the gastrointestinal tract, but most frequently the terminal ileum and colon. Bowel inflammation is transmural and discontinuous. CD is commonly classified as an autoimmune disease.,function:Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also Relative uptake activity ratio of carnitine to TEA is 11.3.,miscellaneous:Inhibited by emetine, quinidine and verapamil. The IC(50) of emetine is 4.2 uM. Not inhibited by valproic acid.,similarity:Belongs to the major facilitator superfamily. Organic cation transporter family.,subunit:Interacts with PDZK1.,tissue specificity:Strongly expressed in kidney, skeletal muscle, heart and placenta. Highly expressed in intestinal cell types affected by Crohn disease, including epithelial cells. Expressed in CD68 macrophage and CD43 T-cells but not in CD20 B-cells., |
Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |